Please assess the completion status of the following clinical trial:

Trial Title: Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic Fibrosis~* Hospitalized with acute pulmonary exacerbation~* Caused by Pseudomonas aeruginosa or other bacteria against which meropenem would be an appropriate antibiotic treatment~Exclusion Criteria:~* Known allergy to meropenem~* Require less than 3 days of meropenem in the hospital~* Require another systemic Beta-lactam antibiotic to treat a concomitant pathogen~* Known fungal or viral infection~* Females in their 2nd or 3rd trimester of pregnancy~* Moderate to severe renal dysfunction, as defined by a creatinine clearance less than 50 ml/min/1.73m2 (by use of Schwartz method)~* History of solid organ transplantation within previous 6 months~* Active or recent (within 30 days) participation in another antibiotic clinical trial

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Meropenem 3 hour prolonged infusion (Type: EXPERIMENTAL): All 30 participants will receive meropenem as a 3 hour infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).